Bedrijfsoverzicht
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to the development and commercialization of novel synthetic lethality-based cancer therapeutics that specifically target DNA damage response pathways. The company operates within the healthcare sector, specifically the biotechnology industry, which implies a focus on high-risk, high-reward research and development activities aimed at creating innovative treatments for oncology patients. As of the latest available data, the company possesses a market capitalization of $10.50M and employs a workforce of 8 individuals to execute its strategic objectives. With a trailing twelve-month revenue of $285,759, the firm operates on a micro-cap scale, indicating that its current financial operations are primarily driven by research expenditures rather than significant commercial sales volume. The combination of a $10.50M market cap and minimal revenue suggests that the company is in an early-stage development phase where valuation is largely derived from potential future product approvals rather than established cash flows.
Financiële gezondheid
The company reported a revenue of $285,759 for the trailing twelve months, alongside a net income of $-12,599,569 and an EBITDA of $-13,212,121, highlighting a substantial disparity between top-line generation and bottom-line profitability. The significant gap between the modest revenue figure and the deep net loss reveals a cost structure heavily dominated by research and development expenses typical for a clinical-stage biotechnology firm with limited commercialization. Free cash flow stands at $-8,564,504, which indicates that the company is consuming cash reserves to fund its operational and development activities, thereby limiting immediate financial flexibility for external expansion or acquisitions. The gross margin is recorded at 0.0%, reflecting the pre-revenue nature of the business where cost of goods sold is negligible relative to zero sales, while the operating margin of -79205.7% and profit margin of 0.0% underscore the intense burn rate inherent in developing synthetic lethality-based therapeutics. Total cash on hand amounts to $14.60M against zero debt, creating a balance sheet that is purely equity-funded and devoid of any leverage or interest obligations. The current ratio of 5.63 demonstrates robust short-term liquidity, ensuring the company can meet its immediate financial obligations with a significant cushion of cash relative to current liabilities. Furthermore, the return on equity is -74.6% and the return on assets is -41.4%, metrics that reveal that management is currently diluting shareholder value and utilizing assets to generate losses rather than profits, a common characteristic for early-stage biotech ventures.
Waarderingsbeoordeling
The P/E Ratio (TTM) is listed as N/A due to the negative net income, while the forward P/E is reported as -1.39, a metric that is technically distorted by current losses and does not provide a reliable benchmark for earnings trajectory comparisons. The price-to-book ratio is 0.60, indicating that the market values the company at a discount to its book value, a scenario often seen in unprofitable biotechnology firms where the asset base is valued differently than its accounting book value. The price-to-sales ratio stands at 36.74 and the EV/EBITDA is 0.26, suggesting that the market is pricing the stock based on potential future clinical milestones rather than current sales performance or earnings generation. The 52-week high is $2.22 and the 52-week low is $0.55, meaning the current trading price sits within a range that reflects high volatility and uncertainty regarding the timing of the next major catalyst. The beta value of 1.57 indicates that the stock's price volatility is significantly higher than the broader market, moving 1.57 times as much as the market index during periods of fluctuation.
Growth & Income
Revenue growth year-over-year is -98.4%, while earnings growth year-over-year is N/A, illustrating a period of contraction in sales figures likely due to the transition from early clinical phases or inventory adjustments rather than organic business decline. Since earnings growth is not applicable due to the company's loss-making status, the comparison between revenue contraction and earnings reveals that the company is in a phase where revenue recognition is not yet the primary driver of value creation. The dividend yield is N/A and the payout ratio is 0.0%, confirming that the company does not distribute dividends to shareholders. As a non-dividend payer, Aprea Therapeutics, Inc. reinvests all available resources, including its cash reserves, directly back into research and development to advance its lead product candidates rather than providing income to investors. The overall growth and income profile is characterized by negative revenue growth and zero income distribution, which is typical for a clinical-stage company focused entirely on capitalizing on future synthetic lethality-based therapeutics rather than generating current returns.